Want to join the conversation?
Pro forma for transaction and separation of Adient, $JCI is expected to have about $32Bil of revenue in FY16 and $4.5Bil of EBITDA before synergies. Adient is expected to have about $16.6Bil of revenue in FY16 and $1.6Bil of EBITDA. Adient is expected to distribute $2.5-3.5Bil to $JCI in conjunction with spin-off
$WBA is yet to receive US anti-trust clearance for its Rite Aid acquisition. The deadline for the deal expires on January 27.
$BMY plunge 7.2%. No credits to the non-acceleration of approval for lung cancer combination treatment.